imatinib mesylate has been researched along with Histiocytosis, Sinus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biren-Fetz, J; Gaitonde, S; Khan, I; Mohapatra, G; Ni, H; Simons, Y; Singh, A | 1 |
| Averbeck, M; Gebhardt, C; Kurzen, H; Paasch, U; Simon, JC; Stumpp, P; Treudler, R; Ugurel, S | 1 |
2 other study(ies) available for imatinib mesylate and Histiocytosis, Sinus
| Article | Year |
|---|---|
Extended treatment response to imatinib in Rosai-Dorfman disease.
Topics: Adult; Diagnosis, Differential; Female; Histiocytosis, Sinus; Humans; Imatinib Mesylate | 2021 |
A case of cutaneous Rosai-Dorfman disease refractory to imatinib therapy.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Biopsy; Diagnosis, Differential; Follow-Up Studies; Histiocytosis, Sinus; Humans; Imatinib Mesylate; Immunohistochemistry; Magnetic Resonance Imaging; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Skin; Time Factors | 2009 |